Mather Group LLC. Grows Stock Holdings in Stryker Co. (NYSE:SYK)

Mather Group LLC. raised its position in Stryker Co. (NYSE:SYK) by 7.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,937 shares of the medical technology company’s stock after acquiring an additional 418 shares during the quarter. Mather Group LLC.’s holdings in Stryker were worth $1,778,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of SYK. Bremer Bank National Association boosted its position in shares of Stryker by 4.0% during the fourth quarter. Bremer Bank National Association now owns 888 shares of the medical technology company’s stock valued at $266,000 after buying an additional 34 shares during the period. Simon Quick Advisors LLC boosted its holdings in shares of Stryker by 3.0% in the fourth quarter. Simon Quick Advisors LLC now owns 1,158 shares of the medical technology company’s stock valued at $347,000 after purchasing an additional 34 shares during the period. Consolidated Portfolio Review Corp boosted its holdings in shares of Stryker by 3.6% in the fourth quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company’s stock valued at $294,000 after purchasing an additional 34 shares during the period. MBL Wealth LLC boosted its holdings in shares of Stryker by 4.6% in the fourth quarter. MBL Wealth LLC now owns 850 shares of the medical technology company’s stock valued at $255,000 after purchasing an additional 37 shares during the period. Finally, PDS Planning Inc boosted its holdings in shares of Stryker by 3.0% in the third quarter. PDS Planning Inc now owns 1,318 shares of the medical technology company’s stock valued at $360,000 after purchasing an additional 38 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

NYSE SYK opened at $338.97 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97. The stock’s fifty day moving average price is $348.68 and its 200 day moving average price is $316.14. Stryker Co. has a 1 year low of $249.98 and a 1 year high of $361.41. The company has a market cap of $128.97 billion, a price-to-earnings ratio of 41.09, a PEG ratio of 2.70 and a beta of 0.89.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.27 by $0.19. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The firm had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same period in the prior year, the firm earned $3.00 EPS. The firm’s revenue was up 11.8% on a year-over-year basis. As a group, equities research analysts forecast that Stryker Co. will post 11.86 earnings per share for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 0.94%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s payout ratio is 38.79%.

Insider Activity at Stryker

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the sale, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Stryker news, Director Allan C. Golston sold 3,273 shares of the stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the sale, the director now directly owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO William E. Berry, Jr. sold 7,690 shares of the stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the sale, the chief accounting officer now directly owns 3,675 shares in the company, valued at $1,317,414. The disclosure for this sale can be found here. Insiders have sold a total of 212,109 shares of company stock valued at $72,845,768 in the last ninety days. Company insiders own 5.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SYK. Truist Financial boosted their price target on Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a report on Wednesday, January 31st. Roth Mkm upped their target price on Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and upped their target price for the stock from $315.00 to $360.00 in a report on Wednesday, January 31st. Citigroup upped their target price on Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Finally, Royal Bank of Canada upped their target price on Stryker from $360.00 to $386.00 and gave the stock an “outperform” rating in a report on Monday, April 15th. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $340.67.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.